News
Revance To Present New DAXXIFY Data At The American Academy Of Neurology 2024 Annual Meeting
12 Apr 24
Biotech, News, General
BlackBerry, Nurix Therapeutics, Tesla And Other Big Stocks Moving Higher On Tuesday
9 Apr 24
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
GDS Holdings, Coinbase And Other Big Stocks Moving Higher In Monday's Pre-Market Session
11 Mar 24
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Why Bitdeer Technologies Shares Are Trading Higher By 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
4 Mar 24
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
Tesla, Spirit Airlines, New York Community Bancorp And Other Big Stocks Moving Lower On Monday
4 Mar 24
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
Revance Announces Pricing Of $100M Public Offering Of 16M Shares Of Common Stock At A Price Of $6.25/Share
4 Mar 24
News, Offerings
Goldman Sachs Maintains Neutral on Revance Therapeutics, Raises Price Target to $9
1 Mar 24
News, Price Target, Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Revance Therapeutics, Maintains $12 Price Target
29 Feb 24
News, Price Target, Reiteration, Analyst Ratings
Why Butterfly Network Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
29 Feb 24
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
12 Health Care Stocks Moving In Thursday's Intraday Session
29 Feb 24
Movers
Hormel Foods Reports Upbeat Earnings, Joins Pure Storage, Okta, Papa John's International And Other Big Stocks Moving Higher On Thursday
29 Feb 24
News, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
Piper Sandler Maintains Overweight on Revance Therapeutics, Lowers Price Target to $20
29 Feb 24
News, Price Target, Analyst Ratings
Needham Maintains Buy on Revance Therapeutics, Lowers Price Target to $18
29 Feb 24
News, Price Target, Analyst Ratings
Revance Expects 2024 Total Product Revenue, Which Includes Sales Of DAXXIFY And The RHA Collection, To Be At Least $280M
28 Feb 24
News, Guidance
Revance Therapeutics Q4 EPS $(0.62) Beats $(0.72) Estimate, Sales $69.80M Beat $62.63M Estimate
28 Feb 24
Earnings, News
Earnings Scheduled For February 28, 2024
28 Feb 24
Earnings
Earnings Outlook For Revance Therapeutics
27 Feb 24
Earnings
HC Wainwright & Co. Maintains Buy on Revance Therapeutics, Lowers Price Target to $12
23 Feb 24
News, Price Target, Analyst Ratings
12 Health Care Stocks Moving In Friday's Pre-Market Session
2 Feb 24
Movers
Barclays Maintains Overweight on Revance Therapeutics, Lowers Price Target to $10
29 Jan 24
News, Price Target, Analyst Ratings
Press releases
Revance to Present New DAXXIFY® Data at the American Academy of Neurology 2024 Annual Meeting
12 Apr 24
Press Releases
Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
27 Mar 24
Press Releases
Revance Announces Pricing of $100.0 Million Public Offering of Common Stock
4 Mar 24
Press Releases
Revance Announces Proposed Public Offering of Common Stock
4 Mar 24
Press Releases
Revance to Release Fourth Quarter and Full Year 2023 Financial Results on Wednesday February 28, 2024
21 Feb 24
Press Releases
Revance to Participate in Upcoming Investor Conferences
21 Feb 24
Press Releases
Revance Receives Permanent J-Code for DAXXIFY® and Announces Publication of DAXXIFY Pivotal Study (ASPEN-1) Results in Neurology®
2 Feb 24
Press Releases